- Did you mean
- argent
Search results - 6 results
Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
ImmunoAssay (GP5 +/6+ EIA) using the VALGENT (VAL idation of HPV GEN otyping Tests) framework. METHODS: Clinical performance was assessed using 998 unselected, cervical screening samples enriched with 297 ...
Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
efficiency and PCR inhibition. 1300 VALGENT-2 study samples (from women aged 20-60 attending the Scottish cervical cancer screening program) were tested with the index assay and the GP5 +/6+ PCR enzyme ...
Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Cervical Neoplasms Abstract: In 2012, VAL idation of human papillomavirus (HPV) GEN otyping T ests (VALGENT) was initiated to provide a formalized and uniform study framework for comparison and validation of ...
Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
(hrHPV) types is more effective than cytology-based screening. This study completes the diagnostic accuracy assessment conducted previously within the framework of VALGENT-2 (Validation of HPV genotyping ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
Neoplasms Abstract: In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping performance of the INNO-LiPA HPV Genotyping II (INNO-LiPA) within the VALGENT-3 framework. ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
with an internal control probe. Here, we present an analysis of the clinical performance of the LMNX using a sample panel and infrastructure provided by the international VALGENT (Validation of ...